Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

1.

E2F1 binds to the peptide-binding groove within the BIR3 domain of cIAP1 and requires cIAP1 for chromatin binding.

Allègre J, Cartier J, Glorian V, Droin N, Dumetier B, Kayaci C, Berthelet J, Gemble S, Vuillier C, Maillet L, Garrido C, Dubrez L.

PLoS One. 2018 Oct 25;13(10):e0206253. doi: 10.1371/journal.pone.0206253. eCollection 2018.

2.

Correction: DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Micheau O, Solary E, Dubrez L.

Cell Death Dis. 2018 Jul 16;9(8):785. doi: 10.1038/s41419-018-0822-4.

3.

[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma].

Rossi C, Bastie JN.

Rev Med Interne. 2018 May 22. pii: S0248-8663(18)30521-6. doi: 10.1016/j.revmed.2018.04.015. [Epub ahead of print] French.

PMID:
29801709
4.

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A.

Nat Commun. 2018 Apr 12;9(1):1431. doi: 10.1038/s41467-018-03627-9.

5.

Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration.

Wang Q, Delva L, Weinreb PH, Pepinsky RB, Graham D, Veizaj E, Cheung AE, Chen W, Nestorov I, Rohde E, Caputo R, Kuesters GM, Bohnert T, Gan LS.

Fluids Barriers CNS. 2018 Mar 20;15(1):10. doi: 10.1186/s12987-018-0093-6.

6.

Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.

Buffière A, Accogli T, Saint-Paul L, Lucchi G, Uzan B, Ballerini P, Bastie JN, Delva L, Pflumio F, Quéré R.

Leukemia. 2018 Sep;32(9):2062-2065. doi: 10.1038/s41375-018-0081-5. Epub 2018 Feb 28. No abstract available.

PMID:
29535432
7.

E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death.

Vuillier C, Lohard S, Fétiveau A, Allègre J, Kayaci C, King LE, Braun F, Barillé-Nion S, Gautier F, Dubrez L, Gilmore AP, Juin PP, Maillet L.

EMBO Rep. 2018 Feb;19(2):234-243. doi: 10.15252/embr.201744046. Epub 2017 Dec 12.

PMID:
29233828
8.

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A.

Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. No abstract available.

PMID:
29164674
9.

Regulation of E2F1 Transcription Factor by Ubiquitin Conjugation.

Dubrez L.

Int J Mol Sci. 2017 Oct 19;18(10). pii: E2188. doi: 10.3390/ijms18102188. Review.

10.

Mechanical and chemical recycling of solid plastic waste.

Ragaert K, Delva L, Van Geem K.

Waste Manag. 2017 Nov;69:24-58. doi: 10.1016/j.wasman.2017.07.044. Epub 2017 Aug 18. Review.

PMID:
28823699
11.

DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Michaud O, Solary E, Dubrez L.

Cell Death Dis. 2017 May 25;8(5):e2816. doi: 10.1038/cddis.2017.222. Erratum in: Cell Death Dis. 2018 Jul 16;9(8):785.

12.

Long-term stability of cellulose acetate butyrate thin films for nuclear certified reference materials.

Buják R, Delva L, Erkoç M, Bauwens J, Jakopič R, Vincze L, Aregbe Y, Cardon L.

J Radioanal Nucl Chem. 2017;311(1):877-886. doi: 10.1007/s10967-016-5083-z. Epub 2016 Oct 27.

13.

[CD45 phosphatase, a relevant target for the treatment of acute myeloid leukemia].

Saint-Paul L, Nguyen CH, Bastie JN, Delva L, Quéré R.

Med Sci (Paris). 2016 Dec;32(12):1051-1053. doi: 10.1051/medsci/20163212002. Epub 2017 Jan 3. French. No abstract available.

14.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H.

Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.

15.

CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts.

Saint-Paul L, Nguyen CH, Buffière A, Pais de Barros JP, Hammann A, Landras-Guetta C, Filomenko R, Chrétien ML, Johnson P, Bastie JN, Delva L, Quéré R.

Oncotarget. 2016 Oct 4;7(40):64785-64797. doi: 10.18632/oncotarget.11622.

16.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

17.

Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice.

Chrétien ML, Legouge C, Martin RZ, Hammann A, Trad M, Aucagne R, Largeot A, Bastie JN, Delva L, Quéré R.

Exp Hematol. 2016 Aug;44(8):727-739.e6. doi: 10.1016/j.exphem.2016.04.009. Epub 2016 Apr 27.

PMID:
27130375
18.

Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis.

Roques M, Chretien ML, Favennec C, Lafon I, Ferrant E, Legouge C, Plocque A, Golfier C, Duvillard L, Amoureux L, Bastie JN, Maurin-Bernier L, Dalle F, Caillot D.

Mycoses. 2016 Jun;59(6):383-90. doi: 10.1111/myc.12487. Epub 2016 Mar 2.

PMID:
26931315
19.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

20.

Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre.

Chretien ML, Legouge C, Pagès PB, Lafon I, Ferrant E, Plocque A, Favennec C, Estivalet L, Bottolier-Lemallaz E, Dalle F, Bastie JN, Bernard A, Caillot D.

Clin Microbiol Infect. 2016 Sep;22(9):782-787. doi: 10.1016/j.cmi.2015.12.029. Epub 2016 Jan 22.

Supplemental Content

Loading ...
Support Center